Aromatase inhibitor
Exemestane (Aromasin)
Exemestane (Aromasin) is an oral steroidal aromatase inhibitor with a mean terminal half-life of about 24 hours on the US label; the app lists about 9 hours.1
Exemestane (Aromasin) after one dose: 50% at ~9 h, 25% at 18 h, 12.5% at 27 h.
Drawn from the half-life in the app's model, ~9 h. The model's figures
- Compound
- Exemestane (Aromasin)
- Symbol
- ASN
- Family
- Post-cycle and ancillaries
- Parts
- 13
- References
- 14
- Checked
- Last reviewed . Sources are listed below.
Overview
Exemestane, sold as Aromasin, is an irreversible, steroidal aromatase inactivator supplied as a 25 mg tablet for oral use.1 The US label, with initial US approval in 1999, lists two uses: adjuvant treatment of postmenopausal women with estrogen-receptor positive early breast cancer who have received two to three years of tamoxifen, and treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy.1 The label states that Aromasin is not indicated for the treatment of breast cancer in premenopausal women.1
The Milligram app lists exemestane in its post-cycle therapy group. The trials and labels quoted below enrolled postmenopausal women with early or advanced breast cancer, postmenopausal women at increased risk of breast cancer, or healthy volunteers, and one 2003 study measured exemestane in healthy young males.2,3,4,5 In a 2025 analysis by Blazewicz and colleagues at the National Medicines Institute in Warsaw, 63 of 601 samples seized by police and prosecutors as performance-enhancing drugs declared substances used in post-cycle therapy, and 25.4% of those 63 indicated aromatase inhibitors (anastrozole, letrozole and exemestane) according to the label.6 Among the post-cycle therapy samples, the same record reports the declared active ingredient present in 65.1% and absent in 34.9%, and its 25.4% figure counts three drugs together.6
How it works
The label describes exemestane as structurally related to the natural substrate androstenedione, acting as a false substrate for the aromatase enzyme and processed to an intermediate that binds irreversibly to the active site of the enzyme, causing its inactivation.1 In postmenopausal women the principal source of circulating estrogens is the conversion of adrenal and ovarian androgens to estrogens by aromatase in peripheral tissues.1
In women with advanced breast cancer given 0.5 to 600 mg a day, the label reports estrogen suppression from a 5 mg daily dose, a maximum suppression of at least 85% to 95% at 25 mg, and a 98% reduction in whole body aromatization with 25 mg daily.1 Evans and colleagues (St George's Hospital Medical School, London; Cancer Research, 1992) report that a single 25 mg dose in healthy postmenopausal women reduced plasma estrone, estradiol and estrone sulfate to 35, 28 and 39% of basal values, with maximum suppression observed at 3 days that persisted for at least 5 days.4 The report by di Salle and colleagues of the first phase I trial lists 35 (E1), 39 (E2) and 28% (E1S) for the same 25 mg dose.7 The two reports differ for estradiol and estrone sulfate: 28% and 39% in Evans, 39% and 28% in di Salle.4,7
The label states that exemestane has no detectable effect on adrenal biosynthesis of corticosteroids or aldosterone, and that it has a slight affinity for the androgen receptor (0.28% relative to dihydrotestosterone) while the binding affinity of its 17-dihydrometabolite for the androgen receptor is 100 times that of the parent compound.1 In the label's pharmacodynamics section, daily doses up to 25 mg were associated with small decreases in circulating testosterone, increases in testosterone and androstenedione were observed at daily doses of 200 mg or more, and a dose-dependent decrease in sex hormone binding globulin was observed with daily doses of 2.5 mg or higher.1 In young males, by contrast, 25 and 50 mg daily raised testosterone by 60% and 56%.5 The label also states that one metabolite may have androgenic activity.1
Half-life and pharmacokinetics
Values from the Milligram app's model.
- Half-life
- ~9 h
- Bioavailability
- 42%
- Typical dose
- 12.5–25 mg/day
- Route
- Oral
- Time to peak
- ~1.2 h
| Parameter | App's figure | Source figure |
|---|---|---|
| Half-life | ~9 hours | Label: mean terminal half-life of about 24 hours after oral dosing in healthy postmenopausal women. Mauras and colleagues, 2003: terminal half-life 8.9 hours after a 25 mg dose, in 10 healthy young males.1,5 |
| Bioavailability | 42% | Label: approximately 42% of radiolabeled exemestane was absorbed from the gastrointestinal tract. The label gives no figure called bioavailability.1 |
| Time to peak | ~1.2 hours | Label: mean tmax 1.2 hours in women with breast cancer and 2.9 hours in healthy women. Mauras: highest concentrations 1 hour after a 25 mg dose in males. Evans: peak concentrations reached within 2 hours after 50 to 800 mg.1,5,4 |
| Duration of effect | 72+ hours | Label, single 25 mg dose: maximal suppression of circulating estrogens 2 to 3 days after dosing, persisting for 4 to 5 days.1 |
| Route | Oral | Oral tablet. A high-fat breakfast increased AUC by 59% and Cmax by 39% compared with the fasted state.1 |
The curve below is drawn from the app's half-life of about 9 hours and time to peak of about 1.2 hours, not from the label's half-life of about 24 hours.1 The once-daily interval it offers is the one reported by the TEAM trial (25 mg once a day) and the label.8,1
Level over 5 days
Level, as a share of the peak after one 25 mg dose
As studied: once daily1.
An illustration from a pharmacokinetic model using a half-life of 9 hours. It is not a measured level or a suggested dose.
The label states that the pharmacokinetics of a single 25 mg tablet in fasted healthy males (mean age 32 years) were similar to those in fasted healthy postmenopausal women (mean age 55 years), and its text on this point gives no separate half-life for males.1
Human studies
| Study and year | Design | People | Dose and length | Main result |
|---|---|---|---|---|
| Evans and colleagues, 19924 | Phase I single-dose study, 3 to 4 volunteers per dose, no comparator group described | 29 healthy postmenopausal female volunteers | Single oral doses of 0.5, 5, 12.5, 25, 50, 200, 400 and 800 mg | At 25 mg, plasma estrone, estradiol and estrone sulfate fell to 35, 28 and 39% of basal values. No clinically significant adverse events attributed to the drug were reported, apart from transient eosinophilia in 3 patients. |
| Mauras and colleagues, 20035 | Randomised cross-over of 25 and 50 mg (12 people), plus a pharmacokinetic study (n = 10); no sponsor stated in the source text | Healthy eugonadal young males aged 14 to 26 | 25 mg and 50 mg daily orally, 10 days each, 14-day washout | Estradiol fell 38% (25 mg) and 32% (50 mg) and testosterone rose 60% and 56%; plasma lipids and IGF-I were unaffected. Terminal half-life 8.9 h. The drug was well tolerated. |
| Coombes and colleagues, N Engl J Med 2004 (IES)2 | Double-blind randomised: switch to exemestane vs continue tamoxifen; funder not stated in the source text | 4742 postmenopausal women with primary breast cancer after 2 to 3 years of tamoxifen (2362 exemestane, 2380 tamoxifen) | Switch to exemestane vs tamoxifen for the rest of 5 years; median follow-up 30.6 months | 183 vs 266 first events, hazard ratio 0.68 (95% CI 0.56 to 0.82; P<0.001). Overall survival not significantly different (93 vs 106 deaths). Severe toxic effects of exemestane were rare. |
| Coombes and colleagues, Lancet 2007 (IES)9 | Randomised, intention-to-treat; funder not stated in the source text | 4724 postmenopausal women (2352 exemestane, 2372 tamoxifen) | Switch to exemestane vs tamoxifen; median follow-up 55.7 months | 354 vs 455 events, hazard ratio 0.76 (95% CI 0.66-0.88, p=0.0001). 222 vs 261 deaths, hazard ratio 0.85 (95% CI 0.71-1.02, p=0.08). |
| van de Velde and colleagues, 2011 (TEAM)8 | Phase 3, open-label, 1:1; funded by Pfizer | 9779 postmenopausal women with hormone-receptor-positive breast cancer (4875 sequential, 4904 exemestane alone) | Exemestane 25 mg once a day alone vs tamoxifen 20 mg once a day then exemestane, 5 years | Disease free at 5 years: 85% sequential vs 86% exemestane alone, hazard ratio 0.97 (95% CI 0.88-1.08; p=0.60). |
| Goss and colleagues, 2011 (MAP.3)3 | Randomised, placebo-controlled, double-blind; funded by Pfizer and others | 4560 postmenopausal women at increased risk of breast cancer, median age 62.5 | Exemestane vs placebo; median follow-up 35 months | Invasive breast cancers 11 vs 32, hazard ratio 0.35 (95% CI 0.18 to 0.70; P=0.002). Adverse events in 88% vs 85% (P=0.003). |
Deeper analysis: Intergroup Exemestane Study (IES)
Coombes and colleagues reported IES in the New England Journal of Medicine in 2004 as a double-blind, randomized trial testing whether, after two to three years of tamoxifen, switching to exemestane was more effective than continuing tamoxifen for the remainder of the five years, with disease-free survival as the primary end point.2 There were 183 first events in the exemestane group and 266 in the tamoxifen group after a median follow-up of 30.6 months, the absolute benefit in disease-free survival was 4.7 percent (95 percent CI 2.6 to 6.8) at three years, and contralateral breast cancer occurred in 20 patients in the tamoxifen group and 9 in the exemestane group (P=0.04).2 In the 2007 Lancet report, 354 events on exemestane and 455 on tamoxifen gave a hazard ratio of 0.76 (95% CI 0.66-0.88, p=0.0001), and the overall survival hazard ratio was 0.85 (95% CI 0.71-1.02, p=0.08), or 0.83 (0.69-1.00, p=0.05) with 122 patients with oestrogen-receptor-negative disease excluded.9 Its authors write that their results suggest the early improvements in disease-free survival persist after treatment and "translate into a modest improvement in overall survival".9 Bliss and colleagues (Journal of Clinical Oncology, 2012) describe IES as "an investigator-led study" and report, at a median follow-up of 91 months in 4,052 patients with estrogen receptor positive and 547 with unknown tumors, 352 deaths on exemestane against 405 on tamoxifen (hazard ratio 0.86; 95% CI 0.75 to 0.99; P = .04).10 They call their analyses of breast cancer-free survival and competing events "Exploratory analyses".10 The US label's analysis of all randomized patients at 119 months median follow-up reports 467 deaths (19.9%) on exemestane and 510 (21.5%) on tamoxifen, and states no significant difference between the two groups.1 The funder and the authors' ties to it are not stated in the source text of the 2004, 2007 and 2012 reports.2,9,10
Deeper analysis: TEAM
van de Velde and colleagues (Leiden University Medical Centre; Lancet, 2011) report the Tamoxifen Exemestane Adjuvant Multinational trial, a phase 3 trial conducted in hospitals in nine countries and funded by Pfizer.8 The trial randomly assigned postmenopausal women (median age 64 years) with hormone-receptor-positive breast cancer 1:1 to open-label exemestane alone or following tamoxifen for 5 years, with disease-free survival at 5 years as the primary endpoint.8 At 5 years 4154 (85%) patients in the sequential group and 4186 (86%) in the exemestane alone group were disease free (hazard ratio 0.97, 95% CI 0.88 to 1.08; p=0.60).8 Sequential treatment was associated with a higher incidence of gynaecological symptoms (942 [20%] of 4814 vs 523 [11%] of 4852), venous thrombosis (99 [2%] vs 47 [1%]) and endometrial abnormalities (191 [4%] vs 19 [<1%]) than exemestane alone.8 Musculoskeletal adverse events (2448 [50%] vs 2133 [44%]), hypertension (303 [6%] vs 219 [5%]) and hyperlipidaemia (230 [5%] vs 136 [3%]) were reported more frequently with exemestane alone.8 The authors' interpretation is that "Treatment regimens of exemestane alone or after tamoxifen might be judged to be appropriate options" for these women, and the source text does not state the authors' disclosures.8
Deeper analysis: MAP.3
Goss and colleagues, for the NCIC CTG MAP.3 Study Investigators (Massachusetts General Hospital Cancer Center, Boston), reported in the New England Journal of Medicine in 2011 a randomized, placebo-controlled, double-blind trial of exemestane designed to detect a 65% relative reduction in invasive breast cancer.3 Of 4560 women, 11 invasive breast cancers were detected on exemestane and 32 on placebo at a median follow-up of 35 months (annual incidence 0.19% vs. 0.55%; hazard ratio 0.35; 95% CI 0.18 to 0.70; P=0.002).3 Adverse events occurred in 88% of the exemestane group and 85% of the placebo group (P=0.003), with no significant differences in skeletal fractures, cardiovascular events, other cancers or treatment-related deaths, and the authors report minimal quality-of-life differences.3 The source text states funding by Pfizer and others and does not state the authors' disclosures.3 In the nested bone substudy of 351 women (242 with 2-year follow-up at the time of cutoff), Cheung and colleagues, funded by the Canadian Breast Cancer Research Alliance, report a mean change in total volumetric bone mineral density at the distal radius of -6.1% on exemestane and -1.8% on placebo (difference -4.3%, 95% CI -5.3 to -3.2; p<0.0001), write that two years of exemestane "worsens age-related bone loss in postmenopausal women despite calcium and vitamin D supplementation", and state that the analysis "was done earlier than originally planned" because of the impending announcement of MAP.3 results.11
Deeper analysis: exemestane in healthy young males (Mauras and colleagues)
Mauras and colleagues (Nemours Children's Clinic and Research Programs, Jacksonville, Florida; Journal of Clinical Endocrinology and Metabolism, 2003) recruited healthy eugonadal subjects aged 14 to 26 years.5 Plasma estradiol fell by 38% on 25 mg and 32% on 50 mg, testosterone rose by 60% and 56%, and lipids and IGF-I were unaffected.5 In the pharmacokinetic study the highest concentrations came 1 hour after the 25 mg dose, the terminal half-life was 8.9 hours, and maximal estradiol suppression of 62 +/- 14% was observed at 12 hours.5 The authors describe the drug as well tolerated and add "Long-term efficacy and safety will need further study".5 The source text names no sponsor and lists an erratum to the paper in 2004.5
Doses reported in studies and on labels
| Source | Dose | Frequency | Length |
|---|---|---|---|
| US label, early and advanced breast cancer1 | 25 mg tablet | Once daily after a meal | Early breast cancer: completion of a total of five consecutive years of adjuvant hormonal therapy after two to three years of tamoxifen. Advanced breast cancer: not stated. |
| US label, with a strong CYP 3A4 inducer such as rifampicin or phenytoin1 | 50 mg | Once daily after a meal | Not stated |
| Evans and colleagues, 19924 | 0.5, 5, 12.5, 25, 50, 200, 400 and 800 mg | Single dose | Single dose |
| Mauras and colleagues, 20035 | 25 mg and 50 mg | Daily | 10 days each, 14-day washout |
| IES, Coombes and colleagues, 20079,12 | 25 mg a day (Coleman and colleagues) | Daily | Remainder of a 5-year endocrine treatment period after 2 to 3 years of tamoxifen |
| TEAM, van de Velde and colleagues, 20118 | 25 mg | Once a day | 5 years |
| MAP.3, Cheung and colleagues, 201211 | 25 mg a day | Daily | 2 years in the substudy |
Side effects reported
In IES as reported on the US label, adverse reactions in at least 10% of patients in any group (exemestane vs tamoxifen) were hot flushes (21% vs 20%), fatigue (16% vs 15%), arthralgia (15% vs 9%), headache (13% vs 11%), insomnia (12% vs 9%) and increased sweating (12% vs 10%).1 Discontinuation for adverse reactions was similar in IES (6% vs 5%) and was 12% on exemestane vs 4.1% on placebo in study 027, cardiac ischemic events were 1.6% on exemestane and 0.6% on tamoxifen, and cardiac failure was 0.4% and 0.3%.1 Deaths from any cause were 1.3% on exemestane and 1.4% on tamoxifen in IES, including 6 deaths from stroke vs 2 and 5 from cardiac failure vs 2.1 Clinical fractures were reported in 94 patients receiving exemestane (4.2%) and 71 receiving tamoxifen (3.1%), with osteoporosis 4.6% vs 2.8%, carpal tunnel syndrome 2.4% vs 0.2% and diarrhea 4.2% vs 2.2%.1 The label reports that tamoxifen was associated with a higher incidence of muscle cramps (3.1% vs 1.5%), thromboembolism (2.0% vs 0.9%), endometrial hyperplasia (1.7% vs 0.6%) and uterine polyps (2.4% vs 0.4%).1
In the label's advanced breast cancer program (1058 patients on 25 mg), 3% discontinued because of adverse reactions, and one death was considered possibly related to treatment, an 80-year-old woman with known coronary artery disease who had a myocardial infarction with multiple organ failure after 9 weeks.1
On bone, the label reports percent change in bone mineral density from baseline to 24 months of -3.1% at the lumbar spine and -4.2% at the femoral neck on exemestane vs -0.2% and -0.3% on tamoxifen (IES), and -3.5% and -4.6% vs -2.4% and -2.6% on placebo (study 027), with N=29 vs 38 in the IES columns and N=59 vs 65 in the 027 columns.1 Coleman and colleagues, who analysed 206 evaluable patients for bone density, report fractures in 162 (7%) on exemestane and 115 (5%) on tamoxifen among all 4274 IES participants (odds ratio 1.45 [1.13-1.87]; p=0.003), a different count from the label's 94 (4.2%) and 71 (3.1%) above.12 They write that the survival increase shown with the IES switch "is achieved at the expense of some detriment to skeletal health".12 In the MAP.3 bone substudy the authors note that, to assess the effect on fracture risk, "long-term follow-up is needed".11
In males, Mauras and colleagues describe the drug as well tolerated over 10-day periods.5 A 2003 Eur J Cancer item by Bonomo and colleagues for the Swiss Group for Clinical Cancer Research is titled "Exemestane seems to stimulate tumour growth in men with prostate carcinoma", and its record carries no summary text.13 The label states that, based on findings in animals, male and female fertility may be impaired by treatment with Aromasin.1
Bloodwork and markers
Sources in this part
The app lists total testosterone, free testosterone, estradiol, LH and FSH as markers to monitor. The label reports slight, non-dose-dependent increases in LH and FSH even at low doses as a consequence of feedback at the pituitary level.1 In the first phase I trial, di Salle and colleagues report no effects on plasma LH and FSH in single doses up to 800 mg.7 In young males the 25 and 50 mg daily doses lowered estradiol and raised testosterone.5 No free testosterone result appears in the label or in the studies quoted here.
In study 027 plasma HDL cholesterol was decreased 6 to 9% in exemestane-treated patients, total cholesterol, LDL cholesterol, triglycerides, apolipoprotein-A1, apolipoprotein-B and lipoprotein-a were unchanged, and homocysteine rose 18% against 12% on placebo.1 The label's warnings and precautions cover reductions in bone mineral density (5.1), vitamin D assessment (5.2) and laboratory abnormalities (5.4).1
Regulatory and anti-doping status
Sources in this part
The US label names Pharmacia & Upjohn Company LLC and gives Pfizer Inc as the contact for reporting suspected adverse reactions, and states that Aromasin can cause fetal harm when administered to a pregnant woman.1 The WADA 2026 Prohibited List, in effect from 1 January 2026, names exemestane within S4.1 aromatase inhibitors, part of class S4 hormone and metabolic modulators, which is prohibited at all times, in and out of competition.14 Substances in classes S4.1 and S4.2 are Specified Substances.14
What is not known
Sources in this part
The app's half-life of about 9 hours, the label's about 24 hours and the 8.9 hours in 10 young males come from different studies, and the label's statement that pharmacokinetics in healthy males were similar to those in postmenopausal women gives no male half-life.1,5 A search of PubMed on 16 November 2026 for exemestane in the title or summary text returned 1710 records, and the same search combined with men returned 9 records, with hypogonadal 0 records, with anabolic 9 records and with post cycle 1 record, which is the 2025 analysis of seized samples by Blazewicz and colleagues.6 Mauras and colleagues write that long-term efficacy and safety in males will need further study.5 The label states that safety and effectiveness in pediatric patients have not been established, that the pharmacokinetics have not been studied in pediatric patients, and that the influence of race on pharmacokinetics has not been evaluated.1
Frequently asked questions
What is exemestane?
Exemestane, sold as Aromasin, is an irreversible, steroidal aromatase inactivator supplied as a 25 mg tablet for oral use. The US label lists adjuvant treatment of postmenopausal women with estrogen-receptor positive early breast cancer after two to three years of tamoxifen, and advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy.
What is the half-life of exemestane?
The US label gives a mean terminal half-life of about 24 hours after oral dosing in healthy postmenopausal women. The Milligram app lists about 9 hours, and Mauras and colleagues measured a terminal half-life of 8.9 hours after a 25 mg dose in 10 healthy young males in 2003.
What is the bioavailability of exemestane?
The Milligram app lists a bioavailability of 42%, and the US label states that approximately 42% of radiolabeled exemestane was absorbed from the gastrointestinal tract without giving a figure called bioavailability.
How does exemestane work?
Exemestane acts as a false substrate for the aromatase enzyme and is processed to an intermediate that binds irreversibly to the enzyme's active site, causing its inactivation, which the label also calls suicide inhibition.
Does food change exemestane levels?
A high-fat breakfast increased exemestane AUC by 59% and Cmax by 39% compared with the fasted state, according to the US label.
Is exemestane banned by WADA?
Exemestane is named within S4.1 aromatase inhibitors on the WADA 2026 Prohibited List, part of class S4 hormone and metabolic modulators, which is prohibited at all times, in and out of competition. Substances in classes S4.1 and S4.2 are Specified Substances.
What are the side effects of exemestane?
On the US label's IES data, adverse reactions in at least 10% of patients in any group, exemestane vs tamoxifen, were hot flushes (21% vs 20%), fatigue (16% vs 15%), arthralgia (15% vs 9%), headache (13% vs 11%), insomnia (12% vs 9%) and increased sweating (12% vs 10%). Discontinuation for adverse reactions was 6% vs 5% in IES and 12% vs 4.1% on exemestane vs placebo in study 027.
Does exemestane lower estradiol in young males?
In a 2003 cross-over study of 12 healthy eugonadal young males aged 14 to 26, exemestane lowered plasma estradiol by 38% at 25 mg a day and 32% at 50 mg a day for 10 days, measured 24 hours after the last dose of each period, testosterone rose by 60% and 56%, and the authors describe the drug as well tolerated.
Does exemestane have androgenic activity?
The label reports a slight affinity of exemestane for the androgen receptor (0.28% relative to dihydrotestosterone) and an androgen receptor binding affinity for its 17-dihydrometabolite 100 times that of the parent compound. The label also states that one metabolite may have androgenic activity, and the 1992 report by di Salle and colleagues gives approximately 0.2% of dihydrotestosterone for androgen receptor binding.
What did the Intergroup Exemestane Study find?
In the 2004 report by Coombes and colleagues, 183 first events occurred in the exemestane group and 266 in the tamoxifen group among 4742 women, a hazard ratio of 0.68 (95 percent CI 0.56 to 0.82; P<0.001), with overall survival not significantly different. Later reports give a hazard ratio of 0.76 for disease-free survival at a median of 55.7 months (95% CI 0.66-0.88) and 0.85 for overall survival (95% CI 0.71-1.02, p=0.08), and a 2012 update at a median of 91 months gives 0.86 for overall survival (95% CI 0.75 to 0.99; P = .04).
Guides, tools and comparisons
- Aromasin dosage for menA guide that answers a question on this compound.
- Anastrozole vs aromasinA side-by-side with another compound.
- Previous in Post-cycle and ancillaries: EnclomipheneThe compound before this one in the class.
- Next in Post-cycle and ancillaries: FinasterideThe compound after this one in the class.
References
- Pharmacia & Upjohn Company LLC (Pfizer). AROMASIN (exemestane) tablets, for oral use: US prescribing information. DailyMed, label revised 12/2024. DailyMed label
- Coombes RC, et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004. PMID 15014181
- Goss PE, et al. Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med 2011. PMID 21639806
- Evans TR, et al. Phase I and endocrine study of exemestane (FCE 24304), a new aromatase inhibitor, in postmenopausal women. Cancer Res 1992. PMID 1394219
- Mauras N, et al. Pharmacokinetics and dose finding of a potent aromatase inhibitor, aromasin (exemestane), in young males. J Clin Endocrinol Metab 2003. PMID 14671195
- Blazewicz A, et al. Illegal and falsified medicines self-administrated in not approved post-cycle therapy after the cessation of anabolic-androgenic steroids - qualitative analysis. Front Chem 2025. PMID 40177353
- di Salle E, et al. Exemestane (FCE 24304), a new steroidal aromatase inhibitor. J Steroid Biochem Mol Biol 1992. PMID 1525055
- van de Velde CJ, et al. Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial. Lancet 2011. PMID 21247627
- Coombes RC, et al. Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet 2007. PMID 17307102
- Bliss JM, et al. Disease-related outcomes with long-term follow-up: an updated analysis of the Intergroup Exemestane Study. J Clin Oncol 2012. PMID 22042946
- Cheung AM, et al. Bone density and structure in healthy postmenopausal women treated with exemestane for the primary prevention of breast cancer: a nested substudy of the MAP.3 randomised controlled trial. Lancet Oncol 2012. PMID 22318095
- Coleman RE, et al. Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study. Lancet Oncol 2007. PMID 17267326
- Bonomo M, et al. Exemestane seems to stimulate tumour growth in men with prostate carcinoma. Eur J Cancer 2003. PMID 12957469
- World Anti-Doping Agency. Prohibited List 2026, in effect from 1 January 2026. WADA list